| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/27/2008 | CA2662835A1 Octahydropyrrolo [3, 4-c] pyrrole derivatives and their use as antiviral agents |
| 03/27/2008 | CA2662773A1 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| 03/27/2008 | CA2662673A1 Phenyl derivatives and their use as immunomodulators |
| 03/27/2008 | CA2662574A1 Heterocyclic organic compounds |
| 03/27/2008 | CA2662484A1 Sulfonylpyrazole and sulfonylpyrazoline carboxamidine derivatives as 5-ht6 antagonists |
| 03/27/2008 | CA2662359A1 Pyrrole derivatives useful for the treatment of cytokine-mediated diseases |
| 03/27/2008 | CA2662065A1 Dbait and uses thereof |
| 03/27/2008 | CA2654079A1 Method of inhibiting the transmission of influenza virus |
| 03/27/2008 | CA2646911A1 2- substituted-1alpha, 25-dihydroxy-19,26,27-trinor vitamin d analogs and uses thereof |
| 03/27/2008 | CA2646909A1 2-methylene-1alpha-hydroxy-19,21-dinorvitamin d3 analogs and uses thereof |
| 03/27/2008 | CA2645185A1 2-methylene-1 alpha-hydroxy-18,19,21-trinorvitamin d3 analogs and uses thereof |
| 03/27/2008 | CA2561032A1 Inhibition of cathepsin k activity and the treatment and prevention of disease |
| 03/26/2008 | EP1903058A2 Extracellular novel rage binding protein (en-rage) and uses thereof |
| 03/26/2008 | EP1903057A2 Lipoprotein-regulating medicaments |
| 03/26/2008 | EP1903052A2 APJ receptor ligands and uses thereof |
| 03/26/2008 | EP1903049A1 Crystalline forms of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha -D-mannopyranosyloxy)-phenyl] hexane |
| 03/26/2008 | EP1903046A1 New clopidogrel salt and its crystalline forms |
| 03/26/2008 | EP1903045A1 Pyrazolopyrimidine derivative |
| 03/26/2008 | EP1903044A1 Adenosine Derivatives as A2A Receptor Agonists |
| 03/26/2008 | EP1903043A1 Novel pharmaceutical |
| 03/26/2008 | EP1903041A2 Polymorphic and other crystalline forms of cis-FTC |
| 03/26/2008 | EP1903038A1 N-(1-hetaryl-piperidin-4-yl)-(het)arylamide as EP2 receptor modulators |
| 03/26/2008 | EP1903037A1 1-(hetero)aryl-3-[heteroaryl-piperidin-4yl]-thiourea derivatives as modulators of EP2 receptors |
| 03/26/2008 | EP1903035A2 High purity butoconazole nitrate with specified particle size and a process for preparation of thereof |
| 03/26/2008 | EP1903033A1 Coniosetine, process for preparation and use as pharmaceutical |
| 03/26/2008 | EP1903028A1 Conjugates of glutamate and NMDA receptor channel blockers without excito-toxic effects |
| 03/26/2008 | EP1902756A1 Composition and method for treating skin by administering silybin and piperine/terahydropiperine |
| 03/26/2008 | EP1902755A1 Cosmetic compositions decreasing GM-CSF release induced by nickel salts |
| 03/26/2008 | EP1902732A1 Prophylactic/therapeutic agent for her2-expressing cancer |
| 03/26/2008 | EP1902731A1 Preventive or remedy for glaucoma |
| 03/26/2008 | EP1902729A1 Int6 PROTEIN INVOLVED IN HYPOXIA STRESS INDUCTION AND USE THEREOF |
| 03/26/2008 | EP1902724A2 Antimicrobial compositions |
| 03/26/2008 | EP1902721A1 Ernährungs- und medizinische Zusammensetzungen enthaltend Vaccinium macrocarpon |
| 03/26/2008 | EP1902717A2 Vasopressin antagonist and oxytocin antagonist |
| 03/26/2008 | EP1902716A1 Prophylactic and/or therapeutic agent for motor disorder |
| 03/26/2008 | EP1902715A2 Use of paliperidone for the treatment of psychiatric patients with reduced hepatic function |
| 03/26/2008 | EP1902714A1 Prodrugs of gaba analogs, compositions and uses thereof |
| 03/26/2008 | EP1902713A1 Pharmaceutical composition containing thiazolidinedione compound |
| 03/26/2008 | EP1902712A1 Use of levo-ornidazole for preparing antiparasitic infection drug |
| 03/26/2008 | EP1902711A1 Oral modified release formulations containing Drospirenon and 8-Prenylnaringenin for use in Hormone Replacement Therapy (HRT) |
| 03/26/2008 | EP1902710A1 Pharmaceutical composition and beverage composition comprising l-arginine |
| 03/26/2008 | EP1902709A1 Extended release indapamide tablets and their process of manufacture |
| 03/26/2008 | EP1902706A1 Stable pharmaceutical compositions of tetracyclines in solution, method for obtaining them and their uses |
| 03/26/2008 | EP1902705A1 Injectable pharmaceutical nimesulide solutions |
| 03/26/2008 | EP1902316A2 Method of treating human volume expansion mediated hypertension employing resibufogenin |
| 03/26/2008 | EP1902314A1 Method for evaluating the effects of smoke on bronchioles |
| 03/26/2008 | EP1902068A1 Egfr inhibitors promote axon regeneration |
| 03/26/2008 | EP1902058A2 A process for preparation of methyl-(+)-(s)-alpha-(2-chlorophenyl)-6,7-dihydrothieno(3,2-c)pyridine-5(4h)-acetic acid methyl ester or salts thereof having higher chiral purity and products thereof |
| 03/26/2008 | EP1902057A1 Macrocyclic heterocyclic aspartyl protease inhibitors |
| 03/26/2008 | EP1902055A1 Pyridazine compounds as glycogen synthase kinase 3 inhibitors |
| 03/26/2008 | EP1902054A1 Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof and the therapeutic application of the same |
| 03/26/2008 | EP1902052A1 Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes |
| 03/26/2008 | EP1902051A1 Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| 03/26/2008 | EP1902050A1 Oxazolidinone derivatives and use thereof as antibiotics |
| 03/26/2008 | EP1902049A2 Non-steroidal progesterone receptor modulators |
| 03/26/2008 | EP1902048A1 Oxazolidinone carboxamides containing azetidine and cyclobutane as antibacterial agents |
| 03/26/2008 | EP1902047A2 Carboxamide compound and use of the same |
| 03/26/2008 | EP1902045A1 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament |
| 03/26/2008 | EP1902044A1 5-htx modulators |
| 03/26/2008 | EP1902041A1 New compounds, process for their preparation, intermediates, pharmaceutical compositions and their use in the treatment of 5-ht6 mediated disorders such as alzheimer s desease, cognitive disorders, cognitive impairment associated with schizophrenia, obesity and parkinson's disease |
| 03/26/2008 | EP1902040A2 Polymorphic forms of (s)-1-cyanobutan-2-yl (s)-1-(3-(3-(3-methoxy-4-(oxazol-5-yl) phenyl) ureido) phenyl) ethylcarbamate |
| 03/26/2008 | EP1902039A1 6-oxazol-4-ylmethoxy-alkoxymethyl substituted benzoic acid derivatives forming ppar ligands, methods for production and the use thereof in the form of drugs |
| 03/26/2008 | EP1902037A1 2,4-diamino-pyrimidines used as aurora inhibitors |
| 03/26/2008 | EP1902034A1 Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
| 03/26/2008 | EP1902032A1 Pharmaceutical compounds |
| 03/26/2008 | EP1902031A1 Cathepsin cysteine protease inhibitors |
| 03/26/2008 | EP1902030A1 Substituted quinolones ii |
| 03/26/2008 | EP1902029A1 Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarb-onitrile and methods of preparing the same |
| 03/26/2008 | EP1902028A2 Histamine h3 receptor antagonists |
| 03/26/2008 | EP1902027A1 3-spir0cycl0pr0pyl2-0xind0le kinase inhibitors |
| 03/26/2008 | EP1902025A1 Kinase inhibitors |
| 03/26/2008 | EP1902024A2 Kinase inhibitors |
| 03/26/2008 | EP1902020A1 Derivatives of seleno-amino acids |
| 03/26/2008 | EP1902017A1 Antiviral compounds and methods |
| 03/26/2008 | EP1901820A2 Method for reducing levels of disease associated proteins |
| 03/26/2008 | EP1901778A2 Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds |
| 03/26/2008 | EP1901776A1 Novel medicinal combinations which are used for treating respiratory tract diseases and contain beta-2 long-acting agonists and at least one other type of active substance |
| 03/26/2008 | EP1901768A1 Methods of modulating il-23 activity; related reagents |
| 03/26/2008 | EP1901765A1 Intralesional treatment of psoriasis |
| 03/26/2008 | EP1901755A1 New pharmaceutical compositions containing hyaluronic acid and collagenase for the topical treatment of wounds, burns and ulcers |
| 03/26/2008 | EP1901754A2 Combination therapy of cancer with azd2171 and gemcitabine |
| 03/26/2008 | EP1901753A1 Multiple sclerosis therapy and diagnosis |
| 03/26/2008 | EP1901752A2 Compositions and methods for viral inhibition |
| 03/26/2008 | EP1901751A1 Alpha-helix mimetics and methods relating to the treatment of fibrosis |
| 03/26/2008 | EP1901750A2 Tumor treatment with gliotoxin derivatives |
| 03/26/2008 | EP1901749A2 Aerosolized fluoroquinolones and uses thereof |
| 03/26/2008 | EP1901748A1 Angiogenesis inhibitors |
| 03/26/2008 | EP1901747A2 Pyrimidine-based cdk inhibitors for treating pain |
| 03/26/2008 | EP1901746A2 4-fluoro-piperidine t-type calcium channel antagonists |
| 03/26/2008 | EP1901745A2 Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators and a farnesyl transferase inhibitor |
| 03/26/2008 | EP1901744A2 Preparations comprising arylazine substituted with a carbonylic moiety to increase the activity of gelatinase a in ocular cells |
| 03/26/2008 | EP1901743A1 Quinoline derivatives as antibacterial agents |
| 03/26/2008 | EP1901742A2 Modulation of cell barrier dysfunction |
| 03/26/2008 | EP1901741A1 Process for synthesizing a cetp inhibitor |
| 03/26/2008 | EP1901740A2 Unit dosage forms of temozolomide |
| 03/26/2008 | EP1901739A2 Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives |
| 03/26/2008 | EP1901738A1 Wortmannin analogs and methods of using same in combination with chemotherapeutic agents |
| 03/26/2008 | EP1901737A1 Use of a steroid sulphatase inhibitor for inhibiting the synthesis of androstenedione and/or testosterone |
| 03/26/2008 | EP1901736A1 Pharmaceutical composition comprising simvastatin and ezetimibe |
| 03/26/2008 | EP1901735A2 Polyphenol type compounds, compositions containing same and use thereof for preventing or treating diseases involving abnormal cell proliferation |